Login/Sign Up
In a 70-year-old male with a 15-year history of Type 2 diabetes, what are the clinical implications of his fasting blood glucose rising from 100 mg/dL to 150 mg/dL and his postprandial blood glucose remaining elevated at 250 mg/dL after switching from a combination of Glimepiride/Metformin and Tenegliptin/Metformin to Voglibose 0.2 mg + Metformin 500 mg twice daily? Furthermore, how should his anti-diabetic regimen be optimized to address this suboptimal glycemic control, and what is the clinical significance of trace yeast cells detected in his recent urinalysis?
In a 70-year-old male with a 15-year history of Type 2 diabetes, what are the clinical implications of his fasting blood glucose rising from 100 mg/dL to 150 mg/dL and his postprandial blood glucose remaining elevated at 250 mg/dL after switching from a combination of Glimepiride/Metformin and Tenegliptin/Metformin to Voglibose 0.2 mg + Metformin 500 mg twice daily? Furthermore, how should his anti-diabetic regimen be optimized to address this suboptimal glycemic control, and what is the clinical significance of trace yeast cells detected in his recent urinalysis?
Answered 12 days ago